TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7955181
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (8 g/d of omega-3 fatty acids, 10 capsules of 1.0 g each containing 80.6% ethyl esters of omega-3 fatty acids, providing 4.1 g EPA and 2.8 g DHA)
Study: 2962799
Drug: Thymopentin (TP5)
Normalized name: thymopentin
DrugBank: Thymopentin (DB11996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopentin (TP5) 50 mg administered subcutaneously 3 times weekly for 1 month
Study: 11805451
Drug: Topical heat
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical heat application before exercise in normal controls
Study: 11805451
Drug: Topical heat
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical heat application after exercise in normal controls
Study: 8156047
Drug: Fentanyl 0.250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.250 mg/ml
Study: 8156047
Drug: Sufentanil 0.050
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 0.050 mg/ml
Study: 31934793
Drug: Low-dose group
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose group (LDG) - two Iyengar yoga sessions a week
Study: 31934793
Drug: High-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose group (HDG) - three Iyengar yoga sessions a week
Study: 28138765
Drug: Carperitide (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carperitide (0.01 µg/kg/min)
Study: 23278590
Drug: Eltrombopag 50
Normalized name: eltrombopag 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag 50 mg daily for up to 6 weeks (1 cycle) followed by up to 4 weeks off therapy
Study: 20844233
Drug: Eltrombopag treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag treatment
Study: 22047926
Drug: Bupivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine plus fentanyl (1 mL of 50 μg)
Study: 22047926
Drug: Bupivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine plus tramadol (1 mL of 50 mg)
Study: 22047926
Drug: Bupivacaine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine alone (30 mL of 0.25%)
Study: 15790189
Drug: Anastrozole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole (1 mg per day for 2 years)
Study: 9168368
Drug: Hydration solution
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydration solution (5% dextrose)
Study: 3301915
Drug: Listerine antiseptic
Normalized name: Listerine Antiseptic
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Listerine antiseptic (LA) 2 or 4 times daily for 2 weeks
Study: 25771388
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (docosahexaenoic acid and eicosapentaenoic acid, 450‐1300 mg/day)
Study: 21060282
Drug: L-dopa/benserazide (L/B)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa/benserazide (L/B)
Study: 21060282
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (both PPX and L/B)
Study: 7895551
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg lansoprazole once daily
Study: 22122999
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg lansoprazole once daily
Study: 1306600
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of placebo with two 50 mg ketoprofen capsules
Study: 1752851
Drug: Intramuscular route
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular route of administration
Study: 18626633
Drug: Immediate Release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate Release (IR) propiverine (10, 15, 30 mg)
Study: 18626633
Drug: Oral propiverine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propiverine solution (15 mg)
Study: 10870872
Drug: Zaleplon 20
Normalized name: Zaleplon
DrugBank: Zaleplon (DB00962)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zaleplon 20 mg
Study: 11851645
Drug: Zopiclone 7.5
Normalized name: zopiclone 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone 7.5 mg (active control)
Study: 7536481
Drug: Aprotinin (250,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (250,000 KIU added to cardiopulmonary bypass prime solution and 250,000 KIU infused intravenously over 30 minutes before bypass)
Study: 1911011
Drug: Inhalation induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation induction of anaesthesia with isoflurane and nitrous oxide in oxygen with 5% carbon dioxide
Study: 1911011
Drug: Inhalation induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation induction of anaesthesia with isoflurane and nitrous oxide in oxygen without 5% carbon dioxide
Study: 15814512
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine infusion
Study: 29514333
Drug: Infusion-end plasma
Normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion-end plasma morphine concentrations
Study: 29777633
Drug: Daily terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily terbutaline (8 × 0.5 mg) with habitual training
Study: 29777633
Drug: Daily terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily terbutaline (8 × 0.5 mg) with resistance training
Study: 29777633
Drug: Daily terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily terbutaline (8 × 0.5 mg) with endurance training
Study: 26797412
Drug: HP‐HMB (high‐protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP‐HMB (high‐protein oral nutritional supplement)
Study: 20667004
Drug: Saline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (100 μg kg⁻¹)
Study: 20667004
Drug: Chlorphenamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorphenamine (100 μg kg⁻¹)
Study: 10451784
Drug: Saquinavir-SGC 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir-SGC 1200 mg administered 3 times daily
Study: 10451784
Drug: Hard gelatin
Normalized name: Hard Gelatin Capsule Shell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hard gelatin capsule (HGC) formulation 600 mg administered 3 times daily
Study: 8904053
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of pethidine after atropine premedication (pre‐sedated group)
Study: 55267
Drug: metisoprinol at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: metisoprinol at the dose of 50 mg/kg/day, divided t.i.d., by mouth for 12 days
Study: 26230903
Drug: Zinc acetate
Normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc acetate alone as first-line therapy (n=9)
Study: 26230903
Drug: Zinc acetate
Normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc acetate as maintenance therapy after D-penicillamine (n=12)
Study: 21188849
Drug: Acetaminophen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (600 mg/codeine) (60 mg)
Study: 18601850
Drug: Gastrodin injection
Normalized name: Gastrodia elata whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrodin injection (1,000 mg administered via intravenous drip infusion for 4 weeks)
Study: 16525098
Drug: Azithromycin 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 1,000 mg for three days followed by azithromycin 1,000 mg plus chloroquine 600 mg on days 1 and 2, and azithromycin 1,000 mg plus chloroquine 300 mg on day 3
Study: 16525098
Drug: Chloroquine 600
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine 600 mg on days 1 and 2, then 300 mg on day 3
Study: 12641516
Drug: Thalidomide, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide, 200 mg daily for 2 weeks
Study: 28609128
Drug: Micronized progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized progesterone (utrogestran®) at 100 mg
Study: 21810018
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of bevacizumab (1.25 mg)
Study: 16689808
Drug: 5% sodium
Normalized name: Dextrose 5% and 0.45% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% sodium lauryl sulfate solution
Study: 16689808
Drug: 10% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% sodium lauryl sulfate solution
Study: 9290025
Drug: Extrarenal alterations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extrarenal alterations induced by ARF treatment.
Study: 29315164
Drug: Strength Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength Training Group (STG) - 10 weeks of strength training including plyometric, sprint, and resistance training, performed twice weekly in addition to normal running.
Study: 27555187
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural block (CEB, 0.75 mL/kg of 0.25% bupivacaine)
Study: 24722560
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharomyces boulardii 750 mg/day for 6 weeks
Study: 22251037
Drug: Interim Restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interim Restorative Treatment (IRT) using FUJI IX
Study: 11484954
Drug: Docetaxel (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (100 mg/m2) + Mitoxantrone (20 mg/m2) + G-CSF (150 mcg/m2/d s.c.)
Study: 28237506
Drug: Antidepressant medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medication (specific medications not detailed)
Study: 11700398
Drug: Isonitrogenous control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isonitrogenous control amino acid solution
Study: 9578795
Drug: Conventional eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional eye patches
Study: 3499182
Drug: Dalargin (1-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalargin (1-4 mg)
Study: 7348120
Drug: Nalorphine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalorphine (5 mg)
Study: 21274983
Drug: Placebo (NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (NaCl solution)
Study: 18030228
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg once daily for 8 weeks
Study: 26078574
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg once daily for 2 weeks
Study: 3077320
Drug: Cognitive-behavioral group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral group therapy (stress inoculation training)
Study: 30502505
Drug: Lusutrombopag (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lusutrombopag (3 mg once daily for up to 7 days)
Study: 26453483
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (LPD) 0.8 g/kg/day
Study: 19562716
Drug: Oral branched-chain
Normalized name: Machilus thunbergii branch extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral branched-chain amino acids (BCAAs) 12.45 g/day for at least 1 year
Study: 2676391
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy including positive end-expiratory pressure (PEEP)
Study: 26048096
Drug: Dacomitinib 30
Normalized name: dacomitinib 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacomitinib 30 mg
Study: 21985413
Drug: 135 mg
Normalized name: cocaine 135 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 135 mg minocycline tablet formulation
Study: 19282143
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (sulfasalazine, methotrexate, prednisolone)
Study: 19282143
Drug: Monotherapy (sulfasalazine)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (sulfasalazine)
Study: 15001600
Drug: Oral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral glutamine (0.7 g/kg.d)
Study: 15001600
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (rhGH) (0.3 mg/kg.wk)
Study: 12042546
Drug: Surfaxin lavage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfaxin lavage (8 mL/kg dilute Surfaxin 2.5 mg/mL, instilled into each lung, repeated twice, final lavage with 10 mg/mL)
Study: 30232735
Drug: Oral ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketamine
Study: 2110937
Drug: Guar gum
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar gum (5 g t.i.d. with meals)
Study: 29098875
Drug: Saline and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline and placebo tablets (control group)
Study: 23609341
Drug: Sequential (exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential (exercise first)
Study: 14676740
Drug: 0.625 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg/day conjugated equine estrogen only
Study: 14676740
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus 2.5 mg/day medroxyprogesterone acetate
Study: 10731503
Drug: Iron and
Normalized name: beef,iron and wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron and folic acid supplements with zinc (15 mg Zn)
Study: 3890398
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (20 micrograms dose)
Study: 31932389
Drug: Topical Dynamiclear
Normalized name: Dynamiclear Oro Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Dynamiclear
Study: 28873333
Drug: Echocardiography-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echocardiography-guided therapy
Study: 24816691
Drug: Palatal implant
Normalized name: malate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palatal implant surgery
Study: 16207152
Drug: rostafuroxin 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: rostafuroxin 0.15 mg/day
Study: 16207152
Drug: rostafuroxin 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rostafuroxin 0.5 mg/day
Study: 16207152
Drug: rostafuroxin 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rostafuroxin 1.5 mg/day
Study: 16207152
Drug: rostafuroxin 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: rostafuroxin 5.0 mg/day
Study: 16207152
Drug: rostafuroxin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: rostafuroxin (all doses)
Study: 1820641
Drug: Daily artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daily artesunate regimen (200 mg initial dose followed by 100 mg daily for 4 days)
Study: 1820641
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily artesunate regimen (100 mg 12 hourly for 2 doses on the first day, followed by 50 mg 12 hourly for another 8 doses)
Study: 319116
Drug: Indoprofen (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoprofen (800 mg/day)
Study: 21969851
Drug: UC781 gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: UC781 gel 0.25%
Study: 21969851
Drug: UC781 gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: UC781 gel 0.1%
Study: 11432470
Drug: Standard uncoated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard uncoated ECC with systemic heparin 400 IE/kg
Study: 9928752
Drug: Nitrendipine 20
Normalized name: nitrendipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine 20 mg
Study: 2557274
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (2 puffs of 2 mg each twice daily)
Study: 2557274
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 puffs twice daily)
Study: 27278517
Drug: Moderate catheter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate catheter stability VisiTag setting (3-mm distance limit for at least 5 s, minimum contact force of 8 g over 25% of the set time period, target FTI ≥300 g*s)
Study: 27278517
Drug: Strict catheter
Normalized name: Euphrasia stricta extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strict catheter stability VisiTag setting (3-mm distance limit for at least 10 s, minimum contact force of 10 g over 50% of the set time period, target FTI ≥400 g*s)
Study: 11478144
Drug: Concurrent use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent use of ondansetron and dexamethasone (DEX group)
Study: 3301606
Drug: Cisapride, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride, 10 mg three times daily, orally, before meals
Study: 2806497
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of cold dry air for 4 minutes
Study: 30686542
Drug: Citrate Dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrate Dialysis Fluid (CDF) with 1mmol/L of citrate
Study: 30686542
Drug: Acetate Dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetate Dialysis Fluid (ADF) with 3mmol/L of acetate
Study: 16249508
Drug: Inhaled carbon
Normalized name: carbon dioxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled carbon monoxide (500 ppm)
Study: 1693732
Drug: Felodipine ER
Normalized name: Felodipine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine ER 5 mg
Study: 7933821
Drug: Human atrial
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human atrial natriuretic peptide (ANP) at 0.20 micrograms/kg/min i.v. for 24 hours or 0.08 micrograms/kg/min i.a. for 8 hours, with furosemide or mannitol or no diuretic.
Study: 7933821
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Group II) treated with diuretics or no diuretic, without ANP.
Study: 31140342
Drug: Second generation
Normalized name: Second generation cephalosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second generation antipsychotics in patients with substance use
Study: 31140342
Drug: Second generation
Normalized name: Second generation cephalosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second generation antipsychotics in patients without substance use
Study: 26160525
Drug: Melatonin 3
Normalized name: melatonin 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 3 mg t.i.d. for 1 month
Study: 23307258
Drug: FLOT regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLOT regimen (oxaliplatin 85 mg/m², docetaxel 50 mg/m², leucovorin 200 mg/m², 5-FU 1200 mg/m²) administered biweekly
Study: 21217084
Drug: Cisplatin 50
Normalized name: cisplatin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 50 mg/m(2) weekly × nine cycles
Study: 21217084
Drug: Cisplatin 75
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m(2) every 21 days × six cycles (Control)
Study: 22959217
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (EGb761) 120 mg twice per day
Study: 20534062
Drug: Conventional nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional nutritional rehabilitation therapy
Study: 18198649
Drug: Retention enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retention enema with combination of Chinese and Western drugs
Study: 18198649
Drug: Western drugs
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western drugs alone
Study: 11881888
Drug: Ibuprofen (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (5 mg kg(‐1))
Study: 2676430
Drug: Intranasal glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal glucagon
Study: 12357302
Drug: Oral vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vinorelbine (80 mg/m²) administered after fasting
Study: 12357302
Drug: Oral vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vinorelbine (80 mg/m²) administered after ingestion of a standard continental breakfast
Study: 12357302
Drug: Oral vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vinorelbine (80 mg/m²) in both feeding conditions
Study: 10550358
Drug: Dithranol +
Normalized name: Zithranol
DrugBank: Anthralin (DB11157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dithranol + Tazarotene (combined therapy)
Study: 10550358
Drug: Dithranol (monotherapy)
Normalized name: Zithranol
DrugBank: Anthralin (DB11157)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dithranol (monotherapy)
Study: 7750526
Drug: BCG, 81
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG, 81 mg
Study: 7750526
Drug: BCG, 27
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG, 27 mg
Study: 6370283
Drug: Metoprolol (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (single dose)
Study: 6712861
Drug: Propranolol (chronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (chronic treatment for 28 days)
Study: 6712861
Drug: Metoprolol (chronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (chronic treatment for 28 days)
Study: 31309919
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (50,000 IU every 2 weeks) + n-3 fatty acids (2× 1000 mg/d from flaxseed oil)
Study: 24951467
Drug: CloB2A2 regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CloB2A2 regimen (clofarabine 30 mg/m(2)/day for 4 days, busulfan 3.2 mg/kg/day for 2 days, antithymocyte globulin 2.5 mg/kg/day for 2 days)
Study: 15472771
Drug: Conventional analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional analgesic measures (Control)
Study: 2156887
Drug: Finasteride 25
Normalized name: Finasteride
DrugBank: Finasteride (DB01216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Finasteride 25 mg